This study investigates the use of a cfDNA assay for early cancer detection and minimal residual disease. The cancers included are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.
The study focuses on evaluating the ability of the genome-wide methylome enrichment platform to detect minimal residual disease and relapse in lung cancer. It also looks at the detection of multiple cancer types using this platform.
- Who can participate: Participants aged 40 or older with newly diagnosed or recurrent specific cancer types, or without cancer in the last 5 years, may be eligible.
- Study details: Participants will provide blood samples and clinical data. Those with cancer will have follow-ups and blood draws after treatment. Control participants will have regular follow-ups.
- Study visits: Participants will attend regular visits over a period of up to 3 years.
How understandable was the trial content above?
Hard to understand
Easy to understand